• In the past week, PROCEPT BioRobotics reported second-quarter 2026 results, with sales rising to US$94.5 million from US$79.18 million a year earlier, while net loss widened to US$26.86 million and basic loss per share increased to US$0.47.
• Despite higher losses, management reiterated full-year 2026 revenue guidance of US$390 million to US$410 million and projected a net loss between US$96 million and US$91 million, underscoring a continued focus on top-line expansion as the Aquablation franchise scales.
• With strong quarterly sales growth but reaffirmed full-year loss expectations, we'll examine how this earnings update reshapes PROCEPT BioRobotics' investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT BioRobotics, you need to believe Aquablation and the HYDROS platform can become a widely adopted urology standard while the company tolerates sustained losses to build scale. The latest Q2 results reinforce that trade off: strong sales growth but a wider net loss, with management still guiding to sizeable full year losses. For now, this does not materially change the key near term catalyst of broader Aquablation adoption, or the biggest risk around ongoing operating losses.

In that context, the May 2026 update on the WATER IV prostate cancer program stands out. By advancing Aquablation into localized prostate cancer, PROCEPT is working to expand its addressable market beyond benign prostatic hyperplasia, which ties directly into the adoption and utilization catalyst. The current earnings update, with higher revenue but deeper losses, simply underlines how much the company is investing to support these kinds of long duration clinical and commercial initiatives.

Yet against that growth push, investors should still pay close attention to the risk that ongoing operating losses and rising cost pressures could...

PROCEPT BioRobotics' narrative projects $607.5 million revenue and $69.6 million earnings by 2029.

Uncover how PROCEPT BioRobotics' forecasts yield a $22.73 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Some analysts were assuming roughly 26.7% annual revenue growth and a swing to about US$79.3 million in earnings by 2029, which is a far more optimistic path than the consensus view. As you weigh Q2’s higher sales but wider loss alongside long term reimbursement and competition risks, remember that these bullish forecasts could be revised meaningfully, up or down, as new information emerges.

Explore 7 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth as much as 71% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

Interested In Other Possibilities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.